Abstract:Objective: To study the expressions of C-C class chemokine 17 (CCL17), C-C class chemokine 22 (CCL22), and C-C chemokine receptor 4 (CCR4) in newly diagnosed multiple myeloma (NDMM) for analyzing their correlations with clinical features and to preliminarily explore their roles in the development of NDMM. Methods: The study included 40 patients with NDMM and 20 healthy volunteers from the Department of Hematology of the Affiliated Hospital of Zunyi Medical University from July 2020 to December 2022. Peripheral blood, bone marrow, and bone marrow biopsy tissue samples were collected from the two groups. The expression levels of CCL17, CCL22, and CCR4 in patients with NDMM were analyzed using real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry. The mRNA expression levels of CCL17, CCL22, and CCR4 in the bone marrow mononuclear cell (BMMNC) of patients with NDMM were analyzed to assess their correlations with clinical indicators. Results: The mRNA expression levels of CCL17, CCL22, and CCR4 in BMMNC were higher in patients with NDMM than in controls (all P<0.05). The protein expression levels of CCL17 and CCL22 in peripheral blood supernatants and bone marrow supernatants were higher in patients with NDMM than in controls (all P<0.05). The expression levels of CCL17, CCL22, and CCR4 in bone marrow biopsy tissues were higher in patients with NDMM than in controls (all P<0.05). The mRNA expression level of CCL17 was increased in NDMM patients with combined anemia, bone damage, renal damage, and M protein level ≥30 g/L (all P<0.05). The mRNA expression level of CCL22 was increased in NDMM patients with combined anemia, bone damage, and renal damage (all P<0.05). The mRNA expression level of CCR4 was increased in NDMM patients with combined anemia and renal damage (all P<0.05) . Conclusion: CCL17, CCL22, and CCR4 were highly expressed in clinical samples from patients with NDMM compared to those from controls, and they may be involved in the occurrence and development of NDMM.

CCL17, CCL22 and their receptor CCR4 in hematologic malignancies

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Chemokine Receptor CXCR4: an Important Player Affecting the Molecular-Targeted Drugs Commonly Used in Hematological Malignancies.

Enhancing hepatocellular carcinoma management: prognostic value of integrated CCL17, CCR4, CD73, and HHLA2 expression analysis

A review on CXCR4/CXCL12 axis in oncology: No place to hide

[Expression and clinical significance of CCL17, CCL22, and CCR4 in newly diagnosed multiple myeloma]

Progress on CCL5/CCR5 Axis in Cancer

The CCL5/CCR5 Axis in Cancer Progression

Targeting CXCR4 in AML and ALL

CXCR4 as a therapeutic target in acute myeloid leukemia

Targeting chemokines for acute lymphoblastic leukemia therapy

CCL17/CCL22 Predict the Survival and Response to Immune Checkpoint Blockade Therapy of Patients with HNSCC

CCL5/CCR5 axis in human diseases and related treatments

[Research Advance on SDF-1/CXCR4 Axis Associated with Hematological Malignancies: Review].

Role of CXCR4 in the progression and therapy of acute leukaemia

Development and Application of Nanomaterials, Nanotechnology and Nanomedicine for Treating Hematological Malignancies

CXCL12-CXCR4/CXCR7 Axis in Cancer: from Mechanisms to Clinical Applications

Exploring the nexus of nuclear receptors in hematological malignancies

Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies

Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies

[Research Progresses on the Effects of CCL4 on Immune Escape in Tumor Microenvironment]